Item 2.02 Results of Operations and Financial Condition.
In conjunction with the announcement of Richard B. Doubleday's retirement and to
celebrate Mr. Doubleday's accomplishments as disclosed in Item 5.02 below that
include another record quarter, DexCom, Inc. ("DexCom") announced select
preliminary financial results for the third quarter ended September 30, 2020.
DexCom achieved half a billion dollars in revenue in the third quarter, with
revenues of $500.9 million, representing 26% growth over the third quarter of
2019. A full presentation of DexCom's quarterly results will occur at 1:30 PM
PST on Tuesday, October 27, 2020.
The information in this Item 2.02, including Exhibit 99.01 hereto, is furnished
pursuant to Item 2.02 of Form 8-K, and is not deemed to be "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section. The information
contained herein and in the accompanying exhibit is not incorporated by
reference in any filing of DexCom under the Securities Act of 1933, as amended,
or the Exchange Act, whether made before or after the date hereof and
irrespective of any general incorporation language in any filings.
Item 5.02 Departure of Directors or Certain Officers; Election Of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On October 20, 2020, Mr. Doubleday notified DexCom of his intention to retire
from his position as Executive Vice President and Chief Commercial Officer of
DexCom effective December 31, 2020. Mr. Doubleday has decided to retire at this
time in order to spend more time with his family. He joined DexCom in 2009 and
has built a world-class sales organization that allowed DexCom to grow from
approximately $49 million in reported revenue in his first full year to its
current global commercial success. More importantly, through the efforts of Mr.
Doubleday and the many talented members of his sales leadership team, the lives
of countless people with diabetes have been improved by DexCom CGM technology.
In order to support continued growth and implementation of DexCom's commercial
strategy, Mr. Doubleday will continue as a consultant at least through 2021. In
this role, Mr. Doubleday will actively engage with Kevin Sayer, DexCom's
President and Chief Executive Officer, and the rest of DexCom's leadership team.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Number Description
99.01 Press release dated October 26, 2020.
104 Cover Page Interactive Data File (formatted as Inline XBRL)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
DEXCOM, INC. 
